Reports
Sale
Treatment Resistant Depression Market Size, Share, Report: By Drug Class: Selective Serotonin Reuptake Inhibitors (SSRIS), Monoamine Oxidase Inhibitors, Tricyclic Antidepressant, Psychedelics, Others; By Route of Administration: Oral, Others; By End User; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032
Treatment Resistant Depression Market Outlook
The treatment resistant depression market size was valued at USD 3295 million in 2023, driven by the rising awareness of the condition across the 7 major markets. The market is expected to grow at a CAGR of 6.1% during the forecast period of 2024-2032, with the values likely to rise from USD 3494.3 million in 2024 to USD 5590.5 million by 2032.
Treatment Resistant Depression: Introduction
Treatment resistant depression is characterized by the existence of depression symptoms despite continuous treatment. Also known as a major depressive disorder, it includes severe depressive symptoms such as anhedonia (reduced ability to experience pleasure), along with suicidal thoughts and ideation. Repetitive transcranial magnetic stimulation (rTMS), electroconvulsive therapy, and vagus nerve stimulation may be used to treat the condition, depending upon the convenience and severity of the condition in patients.
Treatment Resistant Depression Market Analysis
Treatment resistant depression is a major cause of disability in the population worldwide and is anticipated to affect approximately 21 million adults in the United States alone. Therefore, there has been high treatment resistant depression market demand in recent times.
Since treatment resistant depression is dormant to almost all medications and antidepressants, researchers have been actively involved in developing new and effective treatment strategies for the affected patients. In May 2023, the FDA approved Ketamine, a low-cost dissociative drug as an effective analgesic and general anaesthetic to be used in combination with electroconvulsive therapy. As per the results of the clinical trials, it was revealed that 55% of patients receiving ketamine while 41% of patients getting ECT showed a minimum 50% improvement in their symptoms.
Esketamine, a nasal spray, which is considered a more effective form of Ketamine, has demonstrated promising results in treating the condition. The FDA has also approved Brexanolone (Zulresso) to treat postpartum depression, a severe form of treatment-resistant depression and dextromethorphan-bupropion (Auvelity), which works by modulating the NMDA receptors involved in depression. With the increasing number of drug approvals and development, the treatment resistant depression market value is expected to observe a noticeable increase in the forthcoming years.
Treatment Resistant Depression Market Segmentation
Market Breakup by Drug Class
- Selective Serotonin Reuptake Inhibitors (SSRIS)
- Monoamine Oxidase Inhibitors
- Tricyclic Antidepressant
- Psychedelics
- Others
Market Breakup by Route of Administration
- Oral
- Parenteral
- Others
Market Breakup by End User
- Hospitals
- Specialty Clinics
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Treatment Resistant Depression Market Overview
With heightened awareness of mental health issues and the availability of apt mental healthcare professionals, the United States is projected to lead the treatment resistant depression market share in the future. The existence of influential pharmaceutical companies working at bringing in the latest research-based therapies into the market is a vital growth factor.
In Europe, the market size is considerably large, owing to the presence of a proactive government along with several nonprofit organizations spreading relevant information on combating mental health issues. There is a rising trend towards adopting wellness practices in addition to using medical interventions to treat the condition as well.
The Asia Pacific region, especially Japan, is expected to experience exponential treatment resistant depression market growth in upcoming years. This can be attributed to the decreasing stigmatization of mental health conditions in the area. Moreover, there is significant emphasis on improving the healthcare infrastructure to offer better patient outcomes.
Treatment Resistant Depression Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Pfizer Inc
- Mylan N.V.
- Hikma Pharmaceuticals plc
- AbbVie Inc.
- Melinta Therapeutics, Inc
- Bristol Myers Squibb Company
- GSK Plc.
- Bayer AG
- Perrigo Company plc
- Johnson & Johnson Services, Inc
- Amneal Pharmaceuticals LLC. (U.S.)
- Teva Pharmaceutical Industries Ltd
- Endo Pharmaceuticals plc
- Currax Pharmaceuticals LLC
- Eli Lilly and Company
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by Route of Administration |
|
| Breakup by |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Treatment Resistant Depression Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Treatment Resistant Depression Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Treatment Resistant Depression Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Treatment Resistant Depression Epidemiology Forecast (2017-2032)
5.3.1 Germany Treatment Resistant Depression Epidemiology Forecast (2017-2032)
5.3.2 France Treatment Resistant Depression Epidemiology Forecast (2017-2032)
5.3.3 Italy Treatment Resistant Depression Epidemiology Forecast (2017-2032)
5.3.4 Spain Treatment Resistant Depression Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Treatment Resistant Depression Epidemiology Forecast (2017-2032)
5.4 Japan Treatment Resistant Depression Epidemiology Forecast (2017-2032)
6 Treatment Resistant Depression Market Overview – 7MM
6.1 Treatment Resistant Depression Market Historical Value (2017-2023)
6.2 Treatment Resistant Depression Market Forecast Value (2024-2032)
7 Treatment Resistant Depression Market Landscape – 7MM
7.1 Treatment Resistant Depression: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Treatment Resistant Depression Product Landscape
7.2.1 Analysis by Drug Class
7.2.2 Analysis by Route of Administration
8 Treatment Resistant Depression Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Treatment Resistant Depression Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Treatment Resistant Depression Market Segmentation – 7MM
11.1 Treatment Resistant Depression Market by Drug Class
11.1.1 Market Overview
11.1.2 Selective Serotonin Reuptake Inhibitors (SSRIS)
11.1.3 Monoamine Oxidase Inhibitors
11.1.4 Tricyclic Antidepressant
11.1.5 Psychedelics
11.1.6 Others
11.2 Treatment Resistant Depression Market by Route of Administration
11.2.1 Market Overview
11.2.2 Oral
11.2.3 Parenteral
11.2.4 Others
11.3 Treatment Resistant Depression Market by End User
11.3.1 Market Overview
11.3.2 Hospitals
11.3.3 Specialty Clinics
11.3.4 Others
11.4 Treatment Resistant Depression Market by Distribution Channel
11.4.1 Hospital Pharmacy
11.4.2 Retail Pharmacy
11.4.3 Online Pharmacy
11.5 Treatment Resistant Depression Market by Region
11.5.1 Market Overview
11.5.2 United States
11.5.3 EU-4 and the United Kingdom
11.5.3.1 Germany
11.5.3.2 France
11.5.3.3 Italy
11.5.3.4 Spain
11.5.3.5 United Kingdom
11.5.4 Japan
12 United States Treatment Resistant Depression Market
12.1 Treatment Resistant Depression Market Historical Value (2017-2023)
12.2 Treatment Resistant Depression Market Forecast Value (2024-2032)
12.3 Treatment Resistant Depression Market by Drug Class
12.4 Treatment Resistant Depression Market by Route of Administration
13 EU-4 and United Kingdom Treatment Resistant Depression Market
13.1 Treatment Resistant Depression Market Historical Value (2017-2023)
13.2 Treatment Resistant Depression Market Forecast Value (2024-2032)
13.3 Germany Treatment Resistant Depression Market Overview
13.3.1 Treatment Resistant Depression Market by Drug Class
13.3.2 Treatment Resistant Depression Market by Route of Administration
13.4 France Treatment Resistant Depression Market Overview
13.4.1 Treatment Resistant Depression Market by Drug Class
13.4.2 Treatment Resistant Depression Market by Route of Administration
13.5 Italy Treatment Resistant Depression Market Overview
13.5.1 Treatment Resistant Depression Market by Drug Class
13.5.2 Treatment Resistant Depression Market by Route of Administration
13.6 Spain Treatment Resistant Depression Market Overview
13.6.1 Treatment Resistant Depression Market by Drug Class
13.6.2 Treatment Resistant Depression Market by Route of Administration
13.7 United Kingdom Treatment Resistant Depression Market Overview
13.7.1 Treatment Resistant Depression Market by Drug Class
13.7.2 Treatment Resistant Depression Market by Route of Administration
14 Japan Treatment Resistant Depression Market
14.1 Treatment Resistant Depression Market Historical Value (2017-2023)
14.2 Treatment Resistant Depression Market Forecast Value (2024-2032)
14.3 Treatment Resistant Depression Market by Drug Class
14.4 Treatment Resistant Depression Market by Route of Administration
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 JAPAN PMDA
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnerships and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 Pfizer Inc
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 Mylan N.V.
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 Hikma Pharmaceuticals plc
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 AbbVie Inc.
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 Melinta Therapeutics, Inc
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 Bristol Myers Squibb Company
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 GSK Plc.
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Bayer AG
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 Perrigo Company plc
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 Johnson & Johnson Services, Inc
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
21.11 Amneal Pharmaceuticals LLC. (U.S.)
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisitions
21.11.5 Certifications
21.12 Teva Pharmaceutical Industries Ltd
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisitions
21.12.5 Certifications
21.13 Endo Pharmaceuticals plc
21.13.1 Financial Analysis
21.13.2 Product Portfolio
21.13.3 Demographic Reach and Achievements
21.13.4 Mergers and Acquisitions
21.13.5 Certifications
21.14 Currax Pharmaceuticals LLC
21.14.1 Financial Analysis
21.14.2 Product Portfolio
21.14.3 Demographic Reach and Achievements
21.14.4 Mergers and Acquisitions
21.14.5 Certifications
21.15 Eli Lilly and Company
21.15.1 Financial Analysis
21.15.2 Product Portfolio
21.15.3 Demographic Reach and Achievements
21.15.4 Mergers and Acquisitions
21.15.5 Certifications
22 Treatment Resistant Depression Market- Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 3295 million in 2023, driven by the rising awareness of the condition across the major markets.
The market is anticipated to grow at a CAGR of 6.1% during the forecast period of 2024-2032, likely to reach a market value of USD 5590.5 million by 2032.
The market demand is driven by the increasing incidence of major depression disorders, owing to high-paced, and stressed lifestyle in the population.
The major market trend involves the rising frequency of drug development and approvals to treat the condition. In 2023, the FDA approved three major treatment resistant depression drugs, namely Esketamine, dextromethorphan-bupropion (Auvelity) and Brexanolone (Zulresso).
Based on drug classes, the market is divided into selective serotonin reuptake inhibitors (SSRIS), monoamine oxidase inhibitors, tricyclic antidepressant, and psychedelics, among others.
Major end users include hospitals and speciality clinics, among others.
The route of administration can be oral and parenteral, among others.
What are the major regional markets for treatment resistant depression, according to the EMR report?
The major regions of the market include the United States, Japan, EU-4 which is segmented into Germany, France, Italy, Spain, and the United Kingdom.
Key players involved in the market are Pfizer Inc., Mylan N.V., Hikma Pharmaceuticals plc, AbbVie Inc., Melinta Therapeutics, Inc., Bristol Myers Squibb Company, GSK Plc., Bayer AG, Perrigo Company plc., Johnson & Johnson Services, Inc., Amneal Pharmaceuticals LLC. (U.S.), Teva Pharmaceutical Industries Ltd., Endo Pharmaceuticals plc, Currax Pharmaceuticals LLC, and Eli Lilly and Company.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER